Topical formulation identified for prolonged graft survival in corneal transplants
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, has announced the publication of key findings on its soluble recombinant human CD83 protein (sCD83) in cornea transplants. The study, conducted in rodents, demonstrates that CD83 can modulate the immune system and promote graft survival...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Transplants / Organ Donations Source Type: news
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Corneal Transplant | Health | Infectious Diseases | Study | Transplants